Cyteir Therapeutics Inc

Company Profile

Cyteir Therapeutics Inc had its IPO on 2021-06-18 under the ticker symbol CYT.

The company operates in the Healthcare sector and Biotechnology industry. Cyteir Therapeutics Inc has a staff strength of 46 employees.

Stock update

Shares of Cyteir Therapeutics Inc opened at $2.78 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.75 - $2.8, and closed at $2.77.

This is a +0.73% increase from the previous day's closing price.

A total volume of 38,461 shares were traded at the close of the day’s session.

In the last one week, shares of Cyteir Therapeutics Inc have increased by +0.36%.

Cyteir Therapeutics Inc's Key Ratios

Cyteir Therapeutics Inc has a market cap of $79.55 million, indicating a price to book ratio of 0.3037 and a price to sales ratio of 0.

In the last 12-months Cyteir Therapeutics Inc’s revenue was $0 with a gross profit of $-16591000 and an EBITDA of $-44502000. The EBITDA ratio measures Cyteir Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cyteir Therapeutics Inc’s operating margin was 0% while its return on assets stood at -17.37% with a return of equity of -28.72%.

In Q1, Cyteir Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Cyteir Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.23 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cyteir Therapeutics Inc’s profitability.

Cyteir Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 2.1526. Its price to sales ratio in the trailing 12-months stood at 0.

Cyteir Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$138.98 million

Total Liabilities

$3.96 million

Operating Cash Flow

$150000.00

Capital Expenditure

$0

Dividend Payout Ratio

0%

Cyteir Therapeutics Inc ended 2024 with $138.98 million in total assets and $0 in total liabilities. Its intangible assets were valued at $138.98 million while shareholder equity stood at $134.98 million.

Cyteir Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $3.96 million in other current liabilities, 35000.00 in common stock, $-150600000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $137.20 million and cash and short-term investments were $137.20 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Cyteir Therapeutics Inc’s total current assets stands at $138.39 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $674000.00 and inventory worth $0.

In 2024, Cyteir Therapeutics Inc's operating cash flow was $150000.00 while its capital expenditure stood at $0.

Comparatively, Cyteir Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.77

52-Week High

$4.22

52-Week Low

$1.13

Analyst Target Price

$2.33

Cyteir Therapeutics Inc stock is currently trading at $2.77 per share. It touched a 52-week high of $4.22 and a 52-week low of $4.22. Analysts tracking the stock have a 12-month average target price of $2.33.

Its 50-day moving average was $2.74 and 200-day moving average was $2.02 The short ratio stood at 5.28 indicating a short percent outstanding of 0%.

Around 1190.5% of the company’s stock are held by insiders while 7567.5% are held by institutions.